Pharmacogenetics of esophageal cancer

Click here for a link to the article.

The Pharmacogenomics Journal advance online publication 10 March 2009; doi: 10.1038/tpj.2009.5

GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer

H Alakus¹, U Warnecke-Eberz¹, E Bollschweiler¹, S P Mönig¹, D Vallböhmer¹, J Brabender¹, U Drebber², S E Baldus³, K Riemann⁴, W Siffert⁴, A H Hölscher¹ and R Metzger¹

1. Department of General, Visceral and Cancer Surgery, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany
2. Institute of Pathology, University of Cologne, Cologne, Germany
3. Institute of Pathology, University of Düsseldorf, Düsseldorf, Germany
4. Institute of Pharmacogenetics, University Hospital Essen, Essen, Germany

Correspondence: Dr R Metzger, Department of General, Visceral and Cancer Surgery, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Kerpener Str. 62, Cologne D-50937, Germany. E-mail: ralf.metzger@uk-koeln.de

Received 14 October 2008; Revised 6 February 2009; Accepted 9 February 2009; Published online 10 March 2009.

Top of page

Abstract

Recent studies have shown an association between the GNAS1 T393C polymorphism and clinical outcome for various solid tumors. In this study, we genotyped 51 patients from an observational trial on cisplatin/5-FU-based neoadjuvant radiochemotherapy of locally advanced esophageal cancer (cT2-4, Nx, M0) and genotyping was correlated with histomorphological tumor regression. The C-allele frequency in esophageal cancer patients was 0.49. Pearson's ²-test showed a significant (P<0.05)>